603718 *ST海利生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.291-25.50112.3265.33411.334
总资产报酬率 ROA (%)0.915-21.1009.8253.9647.242
投入资产回报率 ROIC (%)1.067-23.85511.8545.05110.793

边际利润分析
销售毛利率 (%)61.71872.17260.20451.39458.969
营业利润率 (%)15.482-310.55864.39122.91923.309
息税前利润/营业总收入 (%)16.126-100.06074.19724.41746.493
净利润/营业总收入 (%)13.070-155.51267.01420.77636.898

收益指标分析
经营活动净收益/利润总额(%)102.457-26.04214.352-12.3666.497
价值变动净收益/利润总额(%)-3.672-2.48269.982101.0728.615
营业外收支净额/利润总额(%)-4.279-215.68816.1401.52146.711

偿债能力分析
流动比率 (X)2.6465.3426.9011.3492.073
速动比率 (X)2.1844.8096.3521.1021.622
资产负债率 (%)29.57520.3666.76829.13326.630
带息债务/全部投入资本 (%)9.2301.3860.8430.619-2.041
股东权益/带息债务 (%)854.0026,278.16011,585.74115,234.977-4,661.548
股东权益/负债合计 (%)218.848384.9301,262.056251.985282.786
利息保障倍数 (X)12.60059.389-28.67421.34416.889

营运能力分析
应收账款周转天数 (天)150.105200.502128.418136.280112.325
存货周转天数 (天)284.257394.100263.391381.076420.438